Literature DB >> 15317323

Interleukin-18 is associated with increased severity of atopic dermatitis in children.

Myung Hyun Sohn1, Kyung Eun Lee, Kyu-Earn Kim.   

Abstract

Atopic dermatitis (AD) is a chronic relapsing skin disease characterized by reduced interferon (IFN) gamma production with concurrent up-regulation of interleukin (IL)-4. Recently, it was reported that IL-18, formerly called IFN gamma-inducing factor, induces the production of T helper (Th)2-related cytokines without help from IL-12. This study was performed to evaluate the contribution of IL-18 in the pathogenesis of AD. Significantly higher serum IL-18 concentrations were found in patients with severe AD than in healthy subjects. Under staphylococcal enterotoxin B stimulation, IL-18 secretion was increased in peripheral blood mononuclear cells from patients with AD. There were significant differences in the concentrations of IL-10, IL-12, and soluble Fas ligand between AD patients and normal controls. In conclusion, increased serum IL-18 concentrations may be involved in the pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15317323

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  3 in total

1.  Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients.

Authors:  E Roekevisch; K Szegedi; D P Hack; M E Schram; P C J M Res; J D Bos; M M G Leeflang; R M Luiten; S Kezic; P I Spuls; M A Middelkamp-Hup
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-02-05       Impact factor: 6.166

2.  Evaluation of exposure to secondhand smoke and serum level of interleukin 18 in non-smokers.

Authors:  Alireza Azargoon; Ali Kharazmkia; Nazanin Kordalivand; Mehdi Birjandi; Samareh Mir
Journal:  Ann Med Surg (Lond)       Date:  2022-01-03

3.  Systemic and stratum corneum biomarkers of severity in infant atopic dermatitis include markers of innate and T helper cell-related immunity and angiogenesis.

Authors:  M A McAleer; I Jakasa; G Hurault; P Sarvari; W H I McLean; R J Tanaka; S Kezic; A D Irvine
Journal:  Br J Dermatol       Date:  2018-10-04       Impact factor: 9.302

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.